advertisement

Topcon

Abstract #26896 Published in IGR 12-3

Success and complication rates of trabeculectomies augmented with MMC in the management of glaucoma

Sciriha G; Mercieca F
Malta Medical Journal 2010; 22: 27-33


Glaucoma unresponsive to medical treatment is managed by surgery. Augmentation with mitomycin C (MMC) is considered in patients at high risk of surgery failure. Aim: In this paper we assess and compare the success and complications of this procedure performed in the local state hospital with those of larger international centres. Methods: A retrospective study, of the surgery performed between 2003 and 2007 at St. Luke's Hospital by one surgeon (FM), was conducted. The total number of eyes considered in this analysis was 32. Intraocular pressures and complications up to one year post-operatively were recorded. Results: The mean intraocular pressure decreased from 30mmHg pre-operatively to 18mmHg post-operatively. The mean IOP drop registered was 42%. Of the 32 eyes that underwent trabeculectomy augmented with MMC, 23 were classified as a complete success with IOP remaining below 21mmHg at 1year post-surgery. Six eyes were considered as a partial success since they had an IOP under 21mmHg but this had to be kept under control with the administration of medications. Failure of surgery was classified as uncontrollable IOP, although also on medications. This was seen in 3 eyes. Using the central limit theorem, the significance of the difference in means and difference in percentages of IOP drop and complication rates, between the local state hospital procedures and international centres, were calculated. Conclusion: Incidences obtained from this analysis compare very favourably with results from international studies, showing no significant differences.

G. Sciriha. Department of Ophthalmology, Mater Dei Hospital, Msida, Malta. gabysci@yahoo.com


Classification:

12.8.10 Woundhealing antifibrosis (Part of: 12 Surgical treatment > 12.8 Filtering surgery)



Issue 12-3

Change Issue


advertisement

Oculus